De werkwijze van FAST

FAST richt zich op therapieontwikkeling in de brede zin van de geneesmiddelenwet, inclusief cell-based therapies en gentherapie, waarbij ruimte wordt gegeven aan toekomstige innovaties waar de interventies zich niet enkel richten op een geneesmiddel maar op combinaties van geneesmiddelen (drugs), devices, data en diagnostiek.

Investing in future therapy development

With an extensive network of partners, FAST works on solutions for complex issues in the process of therapy development and makes expertise and advice available within the prioritized focus areas. Social needs and opportunities for the Dutch LSH sector are leading in this.

Support

Supporting innovators in therapy development

Connect

Strengthen connectivity in the ecosystem

Signal

Continuously identifying and addressing bottlenecks and gaps

Strengthen

Through open dialogue about interests of companies and patients

Save the date: RSNN Annual workshop 2022 on 5 September

Jaarbeurs Utrecht